Tranquility Partners LLC Trims Holdings in Pfizer Inc. (NYSE:PFE)

Tranquility Partners LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 13.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,839 shares of the biopharmaceutical company’s stock after selling 1,493 shares during the period. Tranquility Partners LLC’s holdings in Pfizer were worth $283,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in PFE. RB Capital Management LLC grew its holdings in shares of Pfizer by 6.7% in the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 341 shares in the last quarter. Ironwood Wealth Management LLC. grew its holdings in shares of Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after purchasing an additional 400 shares in the last quarter. United Bank grew its holdings in Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after acquiring an additional 290 shares in the last quarter. Ergoteles LLC grew its holdings in Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after acquiring an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp grew its holdings in Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after acquiring an additional 79,887 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on PFE. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Performance

PFE stock traded down $0.01 on Thursday, hitting $25.41. The company’s stock had a trading volume of 4,115,780 shares, compared to its average volume of 42,050,078. The firm has a 50 day moving average of $27.19 and a two-hundred day moving average of $28.76. Pfizer Inc. has a 1 year low of $25.26 and a 1 year high of $40.56. The stock has a market cap of $143.89 billion, a price-to-earnings ratio of 70.57, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the prior year, the firm earned $1.14 EPS. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.